Dimeric L-dopa derivatives as potential prodrugs.

[1]  M. Ricciutelli,et al.  Synthesis of L-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2,5-diketomorpholine as potential prodrug of L-dopa. , 2000, Bioorganic & medicinal chemistry letters.

[2]  F. Blandini,et al.  Protective and symptomatic strategies for therapy of Parkinson's disease. , 1999, Drugs of Today.

[3]  T. Aboul-Fadl,et al.  Metronidazole twin ester prodrugs : synthesis, physicochemical properties, hydrolysis kinetics and antigiardial activity , 1998 .

[4]  F. Omar,et al.  Cyclic amide derivatives as potential prodrugs. Synthesis and evaluation of N-hydroxymethylphthalimide esters of some non-steroidal anti-inflammatory carboxylic acid drugs , 1998 .

[5]  M. Tsai,et al.  SYNTHESIS AND PHARMACOLOGICAL ACTIVITIES OF A NOVEL TRIPEPTIDE MIMETIC DOPAMINE PRODRUG , 1995 .

[6]  R. Welch,et al.  The in vitro degradation of cisatracurium, the R, cis‐R′‐isomer of atracurium, in human and rat plasma , 1995, Clinical pharmacology and therapeutics.

[7]  C. Marsden,et al.  L‐Dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease ‡ , 1987, The Journal of pharmacy and pharmacology.

[8]  N. Bodor,et al.  Improved delivery through biological membranes. 4. Prodrugs of L-dopa. , 1977, Journal of medicinal chemistry.

[9]  H. Timmerman,et al.  Cardiovascular hybrid drugs: combination of more than one pharmacological property in one single molecule , 1996 .

[10]  M. Langlois,et al.  Synthesis of symmetrical pseudopeptides as potential inhibitors of the human immunodeficiency virus-1 protease , 1994 .

[11]  S. Yalkowsky,et al.  A Physical Chemical Basis for the Design of Orally Active Prodrugs , 1980 .